ENLV

EnlivexF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$0.32

Analysis reference price unavailable

Analysis 2026-10-25 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$0.17

Analysis reference price unavailable

Analysis 2026-10-25 · RankAlpha Sentiment Codex

B-

Bear case

35%

Probability

Target price

$0.05

Analysis reference price unavailable

Analysis 2026-10-25 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-25

AI commentary

The $0.1734 October 23 packet anchor is about 15% below the prior baseline's $0.205 October 16 anchor; the packet does not establish the cause. The October 19 restructuring and October 22 reverse-split announcement warrant monitoring, not a claimed causal attribution. Analyst revisions, reliable options and short-interest measures, and sufficiently covered social observations are unavailable; zero-valued sentiment fields denote missing data, not neutral readings. Evidence quality remains low (0.18) and uncertainty high (0.876) in the deterministic prior.

RankAlpha Sentiment Codex - 2026-10-25

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-10-27event1-for-16 reverse share splitMedium impact

Enlivex says its shares will begin split-adjusted trading on October 27. The split does not itself change underlying value, but may add trading volatility; all price targets here use the October 23 pre-split $0.1734 anchor. [#PR-2026-10-22] Company release

2026-12-31catalystConvertible-note repayment or conversionHigh impact

The August amendment increased outstanding note principal to approximately $19.2 million, reduced monthly payments to $1.2 million, and set a variable share-conversion price. Further repayment or conversion may pressure cash or shareholders; a new conversion is not assumed. [#SEC-6K-2026-08-11] SEC filing

2027-01-31catalystCost cuts, trial funding and executionHigh impact

The October 19 plan winds down non-Phase IIb R&D, reduces the workforce by approximately 60%, and cuts management pay. Savings could extend runway, but the filing explicitly warns that additional financing may be needed to fund the trial through topline data and that restructuring could disrupt it. [#SEC-6K-2026-10-19] SEC filing

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-25 • Updated nightlySource: Internal modelMethodology